Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

compared with a 4.1% loss in patients taking Wegovy and placebo. Veru said this difference was statistically significant. The trial, which enrolled 168 patients, tested a 3-mg and 6-mg dose of ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Research found that semaglutide, the active substance in Ozempic and the weight-loss drug Wegovy, could help curb alcohol ...

As well as shedding pounds and controlling diabetes, Ozempic and Wegovy can help you drink less, researchers suggest ...

If you’ve been hearing a lot about GLP-1 receptor agonists like semaglutide, you’re not alone. The popularity of semaglutide, the active ingredient in Ozempic and Wegovy, has skyrocketed in ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...